Researchers analyzed a case of a 66-year-old patient who was diagnosed with prostate cancer infiltrating the rectum along with solitary rectal metastases that were staged using 18F-PSMA-1007 PET/CT. The whole-body scan was able to detect multiple foci of abnormal tracer uptake in the pelvis and abdomen. The PET/CT and contrast-enhanced computed tomography images showed an increased uptake of radiotracer in primary tumor in residual prostate gland infiltrating the neck of urinary bladder, rectum, levator ani, and obturator muscles with pelvic ...
Prostate Cancer
Advertisement
Latest News
New imaging agent for patients with PSMA-negative PCa shows safety and efficacy among tests in breast cancer patients.
18F-PSMA-1007 can offer more advantages regarding biokinetics and production than the standard tracer 68Ga-PSMA-11.
Patients with mCRPC with AR alterations had significantly worse survival outcomes compared with patients with wild-type.
A meta-analysis found that triplet regimens with darolutamide and APP improved survival in mCSPC with high volume of disease.
Pembro plus AAP sustained antitumor activity with acceptable safety signals in patients with mCRPC after 2 years.
PRESTO trial results show adding APA and AAP to ADT improved biochemical PFS in patients with relapsed prostate cancer.
Advertisement
Prostate Cancer Knowledge Hubs
Curated clinical content on prostate cancer types, therapies, and technologies
Conference Coverage
Neoadjuvant platinum-based chemotherapy has been found effective for treating metastatic penile squamous cell carcinoma.
A new study has found an association between neurodevelopmental disorders and testicular seminoma.
CLEAR study results showed that treatment with first-line lenvatinib plus pembrolizumab had clinical benefit at 2 years.
The RACE IT trial finds neoadjuvant radio-immunotherapy followed by radical cystectomy a safe and feasible treatment option.
Patients with mCRPC with AR alterations had significantly worse survival outcomes compared with patients with wild-type.
A meta-analysis found that triplet regimens with darolutamide and APP improved survival in mCSPC with high volume of disease.
Advertisement
Advertisement
Trending
The authors said that “PDEARGs are valuable prognostic predictors and potential therapeutic targets” for patients with ...
Metabolites were shown to have “the highest potential for differences between urine levels in healthy and BC patients."
Smoking increased risk of urothelial carcinoma “more than expected” in patients with certain genetic risk factors.
